ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPG evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AAPG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AAPG
Ascentage Pharma Group International is a biopharmaceutical company focused on developing therapies for hematological malignancies, with two approved products in China (olverembatinib and lisaftoclax) and a pipeline of clinical and preclinical candidates targeting apoptosis pathways.
Key risk: Regulatory approval outside China
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2024.
Tracking 12 clinical trials · 2 catalysts for ASCENTAGE PHARMA GROUP INTERNATIONAL.
Ascentage Pharma Group International is a biopharmaceutical company focused on developing therapies for hematological malignancies, with two approved products in China (olverembatinib and lisaftoclax) and a pipeline of clinical and preclinical candidates targeting apoptosis pathways.
- Ascentage Pharma has two approved products in China: olverembatinib for CML-CP and lisaftoclax, but has not received regulatory approval for either outside of China [sec · filed 2026-04-29].
- As of December 31, 2025, the company had cash and bank balances of RMB2,470.1 million (US$353.2 million) and accumulated losses of RMB7,013.3 million (US$1,002.9 million) [sec · filed 2026-04-29].
- The company's operations have consumed substantial cash since inception, and it expects to continue spending heavily on R&D, clinical trials, and commercialization [sec · filed 2026-04-29].
- Ascentage Pharma relies heavily on the success of olverembatinib and lisaftoclax, and failure of these or other candidates could materially harm the business [sec · filed 2026-04-29].
- The company faces risks related to obtaining additional financing, regulatory approvals, and the inherent uncertainty of clinical development [sec · filed 2026-04-29].
What works
- Ascentage Pharma has achieved regulatory approval for two drug candidates (olverembatinib and lisaftoclax) in China, demonstrating some commercial capability [sec · filed 2026-04-29].
- The company has a pipeline of drug candidates in clinical and preclinical development, providing multiple shots on goal beyond the approved products [sec · filed 2026-04-29].
- As of December 31, 2025, the company held RMB2,470.1 million in cash, providing a runway to fund ongoing operations and trials [sec · filed 2026-04-29].
What to weigh
- Ascentage Pharma has accumulated significant losses (RMB7,013.3 million as of December 31, 2025) and expects to continue incurring operating losses for the foreseeable future [sec · filed 2026-04-29].
- The company has not obtained regulatory approval for olverembatinib or lisaftoclax outside of China, limiting its revenue potential and exposing it to international regulatory risks [sec · filed 2026-04-29].
- Ascentage Pharma will need additional financing to complete development and commercialization of its drug candidates, and failure to secure such funding could harm the business [sec · filed 2026-04-29].
- Many of the company's drug candidates are in early-stage clinical trials, and clinical development is inherently uncertain, with a risk of failure at any stage [sec · filed 2026-04-29].
From the filings
Quoted directly from source documents.
The company had significant cash and accumulated losses as of December 31, 2025.
“As of December 31, 2025 we had RMB2,470.1 million ( US$353.2 million) in cash and bank”
SEC filings · April 29, 2026
The company expects to need additional financing.
“We will need to obtain additional financing to fund our operations, and if we are unable to obtain such financing, we may be unable to complete the development and commercialization of our drug candidates”
SEC filings · April 29, 2026
Clinical development is inherently uncertain.
“Clinical development of drug candidates is inherently uncertain.”
SEC filings · April 29, 2026
Catalyst timeline
- 2028-08-01 · Phase3_Topline · lisaftoclax — Topline data from a global Phase 3 confirmatory study of lisaftoclax (APG-2575) in hematological malignancies.
- 2029-06-30 · Phase3_Topline · olverembatinib — Topline data from a registrational Phase 3 study of olverembatinib in patients with SDH-deficient tumors.
Risks & what to watch (4)›
Key risks
- Regulatory approval outside China — No regulatory approval for olverembatinib or lisaftoclax outside China; failure to obtain could impair revenue [sec · filed 2026-04-29].
- Need for additional financing — Company will need additional financing to fund operations; inability to obtain could halt development [sec · filed 2026-04-29].
- Clinical trial uncertainty — Many drug candidates are early-stage; clinical development is inherently uncertain and may fail [sec · filed 2026-04-29].
- Accumulated losses — Accumulated losses of RMB7,013.3M as of Dec 31, 2025; expects continued operating losses [sec · filed 2026-04-29].
What to watch
- Regulatory decisions on olverembatinib and lisaftoclax outside China, which could significantly impact revenue potential [sec · filed 2026-04-29].
- Progress of ongoing and planned clinical trials for pipeline candidates, especially those in early stages [sec · filed 2026-04-29].
- Ability to secure additional financing to support operations and development activities [sec · filed 2026-04-29].
- Commercial performance of olverembatinib and lisaftoclax in China and any expansion into new markets [sec · filed 2026-04-29].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run ASCENTAGE PHARMA GROUP INTERNATIONAL through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ASCENTAGE PHARMA GROUP INTERNATIONAL facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
28.8 months
D/E 8.55
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~702d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$15K
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 498 | $12K |
| eversource wealth advisors, llc | 95 | $3K |
| royal bank of canada | 6 | $0 |
Short Interest
as of May 19, 2026- % of float
- 0.0%
- Days to cover
- 0.0
- Shares short
- 16
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AAPG short interestFrequently asked questions
What is the AI investment thesis for ASCENTAGE PHARMA GROUP INTERNATIONAL?
Ascentage Pharma Group International is a biopharmaceutical company focused on developing therapies for hematological malignancies, with two approved products in China (olverembatinib and lisaftoclax) and a pipeline of clinical and preclinical candidates targeting apoptosis pathways.
What is ASCENTAGE PHARMA GROUP INTERNATIONAL's next catalyst?
ASCENTAGE PHARMA GROUP INTERNATIONAL's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Global Multicenter Open Label Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in" — expected August 1, 2028.
Who is the CEO of ASCENTAGE PHARMA GROUP INTERNATIONAL?
Dr. Dajun Yang M.D., Ph.D. is the chief executive officer of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG).
Where is ASCENTAGE PHARMA GROUP INTERNATIONAL headquartered?
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) is headquartered in Suzhou, China.
What therapeutic areas does ASCENTAGE PHARMA GROUP INTERNATIONAL focus on?
ASCENTAGE PHARMA GROUP INTERNATIONAL develops therapies across Oncology, Immunology, Dermatology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.